-
1.
公开(公告)号:US20090117154A1
公开(公告)日:2009-05-07
申请号:US12066963
申请日:2006-09-14
申请人: Lai-Xi Wang , Jingsong Wang , Timothy Fouts
发明人: Lai-Xi Wang , Jingsong Wang , Timothy Fouts
IPC分类号: A61K39/21 , C12N7/00 , A61K31/715 , G01N33/566 , C08L77/00
CPC分类号: C07H3/06 , A61K31/70 , A61K31/7004 , A61K31/702 , A61K31/715 , A61K31/716 , A61K31/785 , A61K47/58 , G01N2400/10 , A61K2300/00
摘要: Inhibitors that block the DC-SIGN mediated transmission of the HIV-virus from mucosal infection sites to T-lymphocytes. In one embodiment, the inhibitors include at least one oligosaccharide chain attached to a scaffolding framework in which the number of the oligosaccharide chains attached to the scaffold can be 2, 3, 4 or more. In another embodiment, HIV-I viral infection is treated by administration of a composition including a therapeutically effective amount of an oligosaccharide cluster and/or oligosaccharide/protein cluster binding DC-SIGN, to inhibit DC-SIGN from binding to HIV envelope glycoprotein.
摘要翻译: 阻断DC-SIGN介导的HIV病毒从粘膜感染部位传播到T淋巴细胞的抑制剂。 在一个实施方案中,抑制剂包括连接到支架框架的至少一个寡糖链,其中附着于支架的寡糖链的数目可以是2,3,4或更多。 在另一个实施方案中,通过施用包含治疗有效量的寡糖簇和/或寡糖/蛋白质簇结合DC-SIGN的组合物来治疗HIV-1病毒感染,以抑制DC-SIGN结合HIV包膜糖蛋白。
-
公开(公告)号:US20050221445A1
公开(公告)日:2005-10-06
申请号:US11124027
申请日:2005-05-06
申请人: Anthony Devico , Timothy Fouts , Robert Tuskan
发明人: Anthony Devico , Timothy Fouts , Robert Tuskan
IPC分类号: G01N33/50 , A61K31/7088 , A61K38/00 , A61K39/00 , A61K39/395 , A61K48/00 , A61P31/12 , A61P31/18 , C07K14/005 , C07K14/155 , C07K14/16 , C07K14/705 , C07K14/73 , C07K16/08 , C07K16/10 , C07K16/28 , C07K19/00 , C12N1/15 , C12N1/19 , C12N1/21 , C12N5/10 , C12N15/09 , C12N15/62 , C12Q1/02 , C12Q1/70 , G01N33/15 , G01N33/53 , G01N33/569 , C07H21/04 , C12P21/04
CPC分类号: C07K14/005 , A61K38/00 , A61K39/00 , C07K14/70514 , C07K16/1063 , C07K16/2812 , C07K2317/34 , C07K2319/00 , C07K2319/30 , C07K2319/32 , C07K2319/40 , C07K2319/41 , C07K2319/735 , C12N15/62 , C12N2740/15022 , C12N2740/16122 , G01N33/56983 , G01N33/56988 , G01N2500/00
摘要: The invention relates to chimeric molecules comprising a virus coat sequence and a receptor sequence that can inter-act with each other to form a complex that is capable of binding a co-receptor. Such chimeric molecules therefore exhibit functional properties characteristic of a receptor-coat protein complex and are useful as agents that inhibit virus infection of cells due to occupancy of a co-receptor present on the cell. In particular aspects, the chimeric polypeptide includes an immunodeficiency virus envelope polypeptide, such as that of HIV, SIV, FIV, FeLV, FPV and herpes virus. Receptor sequences suitable for use in a chimeric polypeptide include, for example, CD4 D1D2 and CD4M9 sequences.
摘要翻译: 本发明涉及包含能够相互作用以形成能够结合共受体的复合物的病毒外壳序列和受体序列的嵌合分子。 因此,这样的嵌合分子表现出受体外壳蛋白复合物特征的功能特性,并且可用作由于细胞上存在的共 - 受体的占据而抑制细胞病毒感染的试剂。 在具体方面,嵌合多肽包括免疫缺陷病毒包膜多肽,例如HIV,SIV,FIV,FeLV,FPV和疱疹病毒的多肽。 适用于嵌合多肽的受体序列包括例如CD4 D1D2和CD4M9序列。
-